Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Placebo Surgery Controlled, Double-blinded, Multi-center, Phase 2 Clinical Trial, Evaluating the Efficacy and Safety of VY-AADC02 in Advanced Parkinson's Disease With Motor Fluctuations

Trial Profile

A Randomized, Placebo Surgery Controlled, Double-blinded, Multi-center, Phase 2 Clinical Trial, Evaluating the Efficacy and Safety of VY-AADC02 in Advanced Parkinson's Disease With Motor Fluctuations

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 15 Nov 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs VY AADC (Primary)
  • Indications Parkinson's disease
  • Focus Adverse reactions; Pharmacokinetics; Registrational; Therapeutic Use
  • Acronyms RESTORE-1
  • Sponsors Neurocrine Biosciences; Voyager Therapeutics
  • Most Recent Events

    • 30 Apr 2019 According to a Neurocrine Biosciences media release, data from this trial will be presented at the American Academy of Neurology (AAN) Annual Meeting 2019.
    • 29 Jan 2019 According to a Neurocrine Biosciences media release, the company and Voyager Therapeutics entered into a strategic collaboration under which, after the data readout from this trial, Voyager will either co-commercialise VY-AADC with Neurocrine Biosciences in the US under a 50/50 cost and profit-sharing arrangement and receive milestones and royalties based on ex-US sales, or grant full global commercial rights in exchange for milestone payments and royalties based on global sales.
    • 07 Jan 2019 According to a Voyager Therapeutics media release, if positive, results from RESTORE-1 and RESTORE-2 could potentially form the basis for submission of a biologics license application (BLA) to the FDA for VY-AADC for the treatment of Parkinsons disease.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top